Healthcare diagnostics company Quest Diagnostics (NYSE: DGX) will be reporting earnings tomorrow before market hours. Here’s what you need to know.
Quest beat analysts’ revenue expectations by 1.8% last quarter, reporting revenues of $2.62 billion, up 14.6% year on year. It was a strong quarter for the company, with a narrow beat of analysts’ sales volume estimates and a decent beat of analysts’ EPS estimates.
Is Quest a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Quest’s revenue to grow 10.7% year on year to $2.62 billion, improving from the 1.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.15 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Quest has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 2.5% on average.
Looking at Quest’s peers in the healthcare providers & services segment, only UnitedHealth has reported results so far. It missed analysts’ revenue estimates by 1.7%, delivering year-on-year sales growth of 9.8%.
Read our full analysis of UnitedHealth’s earnings results here.Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
